CardiAMP is under clinical development by BioCardia and currently in Phase III for Myocardial Ischemia. According to GlobalData, Phase III drugs for Myocardial Ischemia does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CardiAMP LoA Report. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CardiAMP overview
BioCardia overview
BioCardia is a regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The company develops biotherapeutic candidates that include a CardiAMP cell therapy system, autologous minimally processed bone marrow cells and an allogeneic off-the-shelf mesenchymal stem a cell product candidate for ischemic systolic heart failure. BioCardia’s CardiAMP cell therapy system comprises a cell potency screening test, a point-of-care cell processing platform, and a biotherapeutic delivery system. The company sells its products through a network of distributors across the US. BioCardia is headquartered in San Carlos, California, the US
For a complete picture of CardiAMP’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
